ATSDR MINIMAL RISK LEVELS (MRLS) FOR HAZARDOUS SUBSTANCES—Continued

[March 1996]

Substance name	CAS No.	Route	Duration	Value	Factors	End point
1,3-DI-CHLORO-PROPENE.	000542–75–6	INHALATION	INTERMEDIATE	0.003 ppm	100	Respiratory.
		INHALATION	CHRONIC	0.002 ppm	100	Respiratory.
1,3-DI-NITRO-BENZENE	000099–65–0	ORAL	ACUTE	0.008 mg/kg/day	100	Reproductive.
		ORAL	INTERMEDIATE	0.0005 mg/kg/day	1000	Hematological.
1,4-DI-CHLORO-BENZENE.	000106–46–7	INHALATION	INTERMEDIATE	0.2 ppm	100	Hepatic.
		ORAL	INTERMEDIATE	0.1 mg/kg/day	100	Hepatic.
1-METHYLNAPHTHALENE.	000090–12–0	ORAL	CHRONIC	0.07 mg/kg/day	1000	Respiratory.
2,3,4,7,8-PENTACHLORO-DI-BENZOFURAN.	057117–31–4	ORAL	ACUTE	0.000001 mg/kg/day	3000	Immunological.
		ORAL	INTERMEDIATE	0.00000003 mg/kg/day.	3000	Hepatic.
2,3,7,8-TETRACHLORO-DIBENZO-P-DIOXIN.	001746–01–6	ORAL	ACUTE	0.0000001 mg/kg/day	1000	Hepatic.
		ORAL	INTERMEDIATE	0.000000001 mg/kg/day.	1000	Reproductive.
		ORAL	CHRONIC	0.000000001 mg/kg/day.	1000	Reproductive.
2,4,6-TRI-CHLORO-PHENOL.	000088–06–2	ORAL	INTERMEDIATE	0.04 mg/kg/day	100	Reproductive.
2,4,6-TRI-NITROTOLUENE.	000118–96–7	ORAL	INTERMEDIATE	0.0005 mg/kg/day	1000	Hepatic.
2,4-DI-NITRO-PHENOL	000051–28–5	ORAL	ACUTE	0.01 mg/kg/day	100	Body Weight.
2,4-DI-NITRO-TOLUENE	000121–14–2	ORAL	ACUTE	0.06 mg/kg/day	1000	Hematological.
		ORAL	INTERMEDIATE	0.05 mg/kg/day	100	Reproductive.
		ORAL	CHRONIC	0.002 mg/kg/day	100	Hematological.
2,6-DI-NITRO-TOLUENE	000606–20–2	ORAL	INTERMEDIATE	0.04 mg/kg/day	100	Neurological.
4,4°-METHYL-ENE-BIS (2-CHLOROANILINE).	000101–14–4	ORAL	CHRONIC	0.003 mg/kg/day	3000	Hepatic.
4,6-DI-NITRO-O-CRESOL.	000534–52–1	ORAL	ACUTE	0.004 mg/kg/day	100	Neurological.
		ORAL	INTERMEDIATE	0.004 mg/kg/day	100	Neurological.

[FR Doc. 96–12991 Filed 5–22–96; 8:45 am]

BILLING CODE 4163–70–P

Food and Drug Administration

Advisory Committee; Science Board to the Food and Drug Administration; Formation of a Subcommittee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the formation of a subcommittee of the Science Board to the Food and Drug Administration (Science Board). This subcommittee has been established to address issues related to science and research in FDA. The subcommittee's preliminary recommendations will be presented to the FDA Science Board for full public discussion at a future Science Board meeting.

FOR FURTHER INFORMATION CONTACT: Susan A. Homire, Office of Science (HF–33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3340.

SUPPLEMENTARY INFORMATION: The Food and Drug Administration (FDA) is announcing the formation of a subcommittee to the Science Board to the Food and Drug Administration. This subcommittee has been established to address issues related to science and research in FDA. The subcommittee will meet several times over the next 6 to 9 months to develop preliminary recommendations for the Science Board on a process for review of research programs within FDA. During this period there will be opportunities for public comment; these opportunities will be announced in the Federal Register at least 15 days prior to each scheduled public meeting. The subcommittee's preliminary recommendations will be presented to the Science Board for full public discussion at a future Science Board meeting. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92–463 (5 U.S.C. app. 2)).

Dated: May 16, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–12877 Filed 5–22–96; 8:45 am]

BILLING CODE 4160–01–F

Investigational Biological Product Trials; Procedure to Monitor Clinical Hold Process; Meeting of Review Committee and Request for Submissions

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a meeting of the clinical hold review committee, which reviews the clinical hold orders that the Center for Biologics Evaluation and Research (CBER) has placed on certain investigational biological product trials. FDA is inviting any interested biological product company to use this confidential mechanism to submit to the committee for its review the name and number of